The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients

INTRODUCTION: Imatinib mesylate is the drug of choice for patients with chronic myeloid leukemia (CML). Imatinib pharmacokinetics is affected by a number of transport proteins and enzymes. MATERIAL AND METHODS: In the present study we evaluated the association of eight polymorphisms in the seven gen...

Descripción completa

Detalles Bibliográficos
Autores principales: Belohlavkova, Petra, Vrbacky, Filip, Voglova, Jaroslava, Racil, Zdenek, Zackova, Daniela, Hrochova, Katerina, Malakova, Jana, Mayer, Jiri, Zak, Pavel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2018
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209720/
https://www.ncbi.nlm.nih.gov/pubmed/30393497
http://dx.doi.org/10.5114/aoms.2018.73538

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209720/
https://www.ncbi.nlm.nih.gov/pubmed/30393497
http://dx.doi.org/10.5114/aoms.2018.73538

Ejemplares similares